The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation
Open accessAbstract
OBJECTIVES: To assess the clinical effectiveness and cost-effectiveness of buprenorphine maintenance therapy (BMT) and methadone maintenance therapy (MMT) for the management of opioid-dependent individuals. DATA SOURCES: Major electronic databases were searched from inception to August 2005. Industry submissions to the National Institute for Health and Clinical Excellence were accessed. REVIEW METHODS: The assessment of clinical effectiveness was based on a review of existing reviews plus an updated search for randomised controlled trials (RCTs). A decision tree with Monte Carlo simulation model was developed to assess the cost-effectiveness of BMT and MMT. Retention in treatment and opiate abuse parameters were sourced from the meta-analysis of RCTs directly comparing flexible MMT with flexible dose BMT. Utilities were derived from a panel representing a societal perspective. RESULTS: Most of the included systematic reviews and RCTs were of moderate to good quality, and focused on short-term (up to 1-year follow-up) outcomes of retention in treatment and the level of opiate use (self-report or urinalysis). Most studies employed a trial design that compared a fixed-dose strategy (i.e. all individuals received a standard dose) of MMT or BMT and were conducted in predominantly young men who fulfilled criteria as opiate-dependent or heroin-dependent users, without significant co-morbidities. RCT meta-analyses have shown that a fixed dose of MMT or BMT has superior levels of retention in treatment and opiate use than placebo or no treatment, with higher fixed doses being more effective than lower fixed doses. There was evidence, primarily from non-randomised observational studies, that fixed-dose MMT reduces mortality, HIV risk behaviour and levels of crime compared with no therapy and one small RCT has shown the level of mortality with fixed-dose BMT to be significantly less than with placebo. Flexible dosing (i.e. individualised doses) of MMT and BMT is more reflective of real-world practice. Retention in treatment was superior for flexible MMT than flexible BMT dosing but there was no significant difference in opiate use. Indirect comparison of data from population cross-sectional studies suggests that mortality with BMT may be lower than that with MMT. A pooled RCT analysis showed no significant difference in serious adverse events with MMT compared with BMT. Although treatment modifier evidence was limited, adjunct psychosocial and contingency interventions (e.g. financial incentives for opiate-free urine samples) appeared to enhance the effects of both MMT and BMT. Also, MMT and BMT appear to be similarly effective whether delivered in a primary care or outpatient clinic setting. Although most of the included economic evaluations were considered to be of high quality, none used all of the appropriate parameters, effectiveness data, perspective and comparators required to make their results generalisable to the NHS context. One company (Schering-Plough) submitted cost-effectiveness evidence based on an economic model that had a 1-year time horizon and sourced data from a single RCT of flexible-dose MMT compared with flexible-dose BMT and utility values obtained from the literature; the results showed that for MMT vs no drug therapy, the incremental cost-effectiveness ratio (ICER) was pound 12,584/quality-adjusted life-year (QALY), for BMT versus no drug therapy, the ICER was pound 30,048/QALY and in a direct comparison, MMT was found to be slightly more effective and less costly than BMT. The assessment group model found for MMT versus no drug therapy that the ICER was pound 13,697/QALY, for BMT versus no drug therapy that the ICER was pound 26,429/QALY and, as with the industry model, in direct comparison, MMT was slightly more effective and less costly than BMT. When considering social costs, both MMT and BMT gave more health gain and were less costly than no drug treatment. These findings were robust to deterministic and probabilistic sensitivity analyses. CONCLUSIONS: Both flexible-dose MMT and BMT are more clinically effective and more cost-effective than no drug therapy in dependent opiate users. In direct comparison, a flexible dosing strategy with MMT was found be somewhat more effective in maintaining individuals in treatment than flexible-dose BMT and therefore associated with a slightly higher health gain and lower costs. However, this needs to be balanced by the more recent experience of clinicians in the use of buprenorphine, the possible risk of higher mortality of MMT and individual opiate-dependent users' preferences. Future research should be directed towards the safety and effectiveness of MMT and BMT; potential safety concerns regarding methadone and buprenorphine, specifically mortality and key drug interactions; efficacy of substitution medications (in particular patient subgroups, such as within the criminal justice system, or within young people); and uncertainties in cost-effectiven
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Psychosocial treatment for opiate abuse and dependence
Mayet, S., Farrell, M., Ferri, M., Amato, L., & Davoli, M. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004330.pub2 · Cited by 106
RetractedPsychosocial treatment for opiate abuse and dependence
Mayet, S., Farrell, M., Ferri, M., Davoli, M., & Amato, L. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004330 · Cited by 12
RetractedPharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
Diagnostic and Statistical Manual of Mental Disorder
Ellsworth, P. D. (1980) · The American Journal of Occupational Therapy · doi:10.5014/ajot.34.12.819a · Cited by 1,700
Endorphins: Profound Behavioral Effects in Rats Suggest New Etiological Factors in Mental Illness
Bloom, F., Segal, D., Ling, N., & Guillemin, R. (1976) · Science · doi:10.1126/science.185694 · Cited by 810
Validation of an index of the quality of review articles
Oxman, A. D., & Guyatt, G. H. (1991) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(91)90160-b · Cited by 786
Philips, Z., Ginnelly, L., Sculpher, M., Claxton, K., Golder, S., Riemsma, R., Woolacoot, N., & Glanville, J. (2004) · Health Technology Assessment · doi:10.3310/hta8360 · Cited by 697
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Stanton, M., & Shadish, W. R. (1997) · Psychological Bulletin · doi:10.1037//0033-2909.122.2.170 · Cited by 586
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577
Effective Medical Treatment of Opiate Addiction
Addiction, N. C. D. P. O. E. M. T. O. O. (1998) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.280.22.1936 · Cited by 577
Amato, L., Davoli, M., A.Perucci, C., Ferri, M., Faggiano, F., & P. Mattick, R. (2005) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.02.007 · Cited by 567
Marsch, L. A. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9345157.x · Cited by 553
Pathways From Heroin Addiction: Recovery Without Treatment
Roffman, R. A., & Biernacki, P. (1988) · Contemporary Sociology · doi:10.2307/2069441 · Cited by 512
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466
Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000) · JAMA · doi:10.1001/jama.283.10.1303 · Cited by 415
Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders
Regier, D. A., Rae, D. S., Narrow, W. E., Kaelber, C. T., & Schatzberg, A. F. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000293483 · Cited by 407
The National Treatment Outcome Research Study (NTORS): 4–5 year follow‐up results
Gossop, M., Marsden, J., Stewart, D., & Kidd, T. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00296.x · Cited by 401
Brewer, D. D., Catalano, R. F., Haggerty, K., Gainey, R. R., & Fleming, C. B. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.931738.x · Cited by 392
Drug and Alcohol Problems among Individuals with Severe Mental Illnesses in South London
Menezes, P. R., Johnson, S., Thornicroft, G., Marshall, J., Prosser, D., Bebbington, P., & Kuipers, E. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.5.612 · Cited by 373
Amato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004147.pub4 · Cited by 370
van den Brink, W., Hendriks, V. M., Blanken, P., Koeter, M. W. J., van Zwieten, B. J., & van Ree, J. M. (2003) · BMJ · doi:10.1136/bmj.327.7410.310 · Cited by 347
Barnard, M., & McKeganey, N. (2004) · Addiction · doi:10.1111/j.1360-0443.2003.00664.x · Cited by 337
The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies
Prendergast, M. L., Podus, D., Chang, E., & Urada, D. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00014-5 · Cited by 335
The Principles of Addiction Medicine
(2007) · Addiction and the Medical Complications of Drug Abuse · doi:10.1201/9781420054446-5 · Cited by 332
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Comparison of buprenorphine and methadone in the treatment of opioid dependence
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1025 · Cited by 305
The Economic and Social Costs of CrimePreprint
Brand, S., & Price, R. J. (2000) · RePEc: Research Papers in Economics · Cited by 303
Drug abuse treatment as an HIV prevention strategy: a review
Sorensen, J. L., & Copeland, A. L. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00104-0 · Cited by 302
NICE: faster access to modern treatments? Analysis of guidance on health technologies
Raftery, J. (2001) · BMJ · doi:10.1136/bmj.323.7324.1300 · Cited by 299
Jones, H. E., Johnson, R. E., Jasinski, D. R., O’Grady, K. E., Chisholm, C. A., Choo, R. E., Crocetti, M., Dudas, R., Harrow, C., Huestis, M. A., et al. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.11.013 · Cited by 295
Contingency management in outpatient methadone treatment: a meta-analysis
Griffith, J. D., Rowan-Szal, G. A., Roark, R. R., & Simpson, D. D. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00068-x · Cited by 291
Mattick, R. P., Ali, R., White, J. M., O'Brien, S., Wolk, S., & Danz, C. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00335.x · Cited by 285
Methadone Maintenance and Addicts' Risk of Fatal Heroin Overdose
Caplehorn, J. R. M., Dalton, M. Y. N. S., Haldar, F., Petrenas, A.-M., & Nisbet, J. G. (1996) · Substance Use & Misuse · doi:10.3109/10826089609045806 · Cited by 253
Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients.
Petry, N. M., & Martin, B. (2002) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.70.2.398 · Cited by 241
Drug misuse and dependence — guidelines on clinical management
Stark, M. M. (1999) · Journal of Clinical Forensic Medicine · doi:10.1016/s1353-1131(99)90051-2 · Cited by 238
Brugal, M. T., Domingo‐Salvany, A., Puig, R., Barrio, G., García de Olalla, P., & De La Fuente, L. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01089.x · Cited by 228
HIV transmission and the cost-effectiveness of methadone maintenance
(2000) · American Journal of Public Health · doi:10.2105/ajph.90.7.1100 · Cited by 228
Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews
(1994) · BMJ · doi:10.1136/bmj.309.6963.1241 · Cited by 224
Contingent take-home incentive: Effects on drug use of methadone maintenance patients.
Stitzer, M. L., Iguchi, M. Y., & Felch, L. J. (1992) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.60.6.927 · Cited by 217
The relationship between maternal use of heroin and methadone and infant birth weight
Hulse, G. K., Milne, E., English, D. R., & Holman, C. D. J. (1997) · Addiction · doi:10.1046/j.1360-0443.1997.9211157117.x · Cited by 211
A 24-Year Follow-up of California Narcotics Addicts
Hser, Y.-I. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820190079008 · Cited by 208
Dolan, K. A., Shearer, J., MacDonald, M., Mattick, R. P., Hall, W., & Wodak, A. D. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00187-x · Cited by 203
Deaths Attributable to Methadone vs Buprenorphine in France
Auriacombe, M. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.1.45 · Cited by 191
Fudala, P. J., Jaffe, J. H., Dax, E. M., & Johnson, R. E. (1990) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1990.67 · Cited by 191
Grabowski, J., Rhoades, H., Stotts, A., Cowan, K., Kopecky, C., Dougherty, A., Moeller, F. G., Hassan, S., & Schmitz, J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300392 · Cited by 185
Roozen, H. G., Boulogne, J. J., van Tulder, M. W., van den Brink, W., De Jong, C. A. J., & Kerkhof, A. J. F. M. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.12.006 · Cited by 183
Methadone Maintenance in Primary Care: A Randomized Controlled Trial
Fiellin, D. A., O'Connor, P. G., Chawarski, M., Pakes, J. P., Pantalon, M. V., & Schottenfeld, R. S. (2001) · JAMA · doi:10.1001/jama.286.14.1724 · Cited by 182
Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis
Farré, M., Mas, A., Torrens, M., Moreno, V., & Camı́, J. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00171-5 · Cited by 180
Gossop, M., Marsden, J., Stewart, D., & Treacy, S. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00211-8 · Cited by 175 · cited 3×
“(1058) 6 heroin dependence/ or opiate addiction/ (5197) 7 WITHDRAWAL SYNDROME/ (8466) 8 SUBSTANCE ABUSE/ (13,158) 9 or/2-8 (29,623) 10 1 and 9 (3802) 11 decision support techniques/ (479) 12 markov.”
O’Connor, P., Oliveto, A., Shi, J., Triffleman, E., Carroll, K., Kosten, T., Rounsaville, B., Pakes, J., & Schottenfeld, R. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00194-6 · Cited by 174
Lingford-Hughes, A. R., Welch, S., & Nutt, D. J. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800321 · Cited by 167
Buprenorphine versus methadone maintenance for the treatment of opioid dependence
Fischer, G., Gombas, W., Eder, H., Jagsch, R., Peternell, A., Stuhlinger, G., Pezawas, L., Aschauer, H. N., & Kasper, S. (1999) · Addiction · doi:10.1046/j.1360-0443.1999.94913376.x · Cited by 164
HIV Sexual Risk Reduction Interventions for Women: A Review
Wingood, G. M., & DiClemente, R. J. (1996) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(18)30344-1 · Cited by 162
Godfrey, C., Stewart, D., & Gossop, M. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00752.x · Cited by 161
Marsden, J., Gossop, M., Stewart, D., Rolfe, A., & Farrell, M. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.285 · Cited by 161
Dijkgraaf, M. G. W., van der Zanden, B. P., de Borgie, C. A. J. M., Blanken, P., van Ree, J. M., & van den Brink, W. (2005) · BMJ · doi:10.1136/bmj.330.7503.1297 · Cited by 156
A meta‐analysis comparing buprenorphine to methadone for treatment of opiate dependence
Barnett, P. G., Rodgers, J. H., & Bloch, D. A. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.9656834.x · Cited by 150
Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs
Prendergast, M. L., Urada, D., & Podus, D. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.69.3.389 · Cited by 148
Double-blind randomized trial of buprenorphine and methadone in opiate dependence
Petitjean, S. A., Stohler, R., Déglon, J., Livoti, S., Waldvogel, D., Uehlinger, C., & Ladewig, D. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00163-0 · Cited by 148
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence
Montoya, I. D., Gorelick, D. A., Preston, K. L., Schroeder, J. R., Umbricht, A., Cheskin, L. J., Lange, W. R., Contoreggi, C., Johnson, R. E., & Fudala, P. J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.004 · Cited by 148
Preston, K. L., Umbricht, A., & Epstein, D. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.4.395 · Cited by 146
Schottenfeld, R. S., Chawarski, M. C., Pakes, J., Pantalon, M. V., Carroll, K. M., & Kosten, T. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.340 · Cited by 145
The cost‐effectiveness of methadone maintenance as a health care intervention
Barnett, P. G. (1999) · Addiction · doi:10.1046/j.1360-0443.1999.9444793.x · Cited by 142
Mortality associated with New South Wales methadone programs in 1994: lives lost and saved
Caplehorn, J. R. M., & Drummer, O. H. (1999) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127675.x · Cited by 141
Curran, H. V., Kleckham, J., Bearn, J., Strang, J., & Wanigaratne, S. (2001) · Psychopharmacology · doi:10.1007/s002130000628 · Cited by 141
Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome
Gerra, G., Borella, F., Zaimovic, A., Moi, G., Bussandri, M., Bubici, C., & Bertacca, S. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.11.017 · Cited by 141
Barnett, P. G., Zaric, G. S., & Brandeau, M. L. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.96912676.x · Cited by 132
Drug Misuse and Dependence – Guidelines on Clinical Management
(1999) · Psychiatric Bulletin · doi:10.1192/pb.23.8.512-c · Cited by 131
Jones, H. E. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00152-6 · Cited by 125
Kosten, T. R., Oliveto, A. H., Feingold, A., Poling, J. C., Sevarino, K. A., McCance‐Katz, E. F., Stine, S. M., Gonzalez, G. M., & Gonsai, K. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00032-2 · Cited by 121
Assistance in developing a custom-made prosthetic eye service.
Gruen, R., Weeramanthri, T., Knight, S., & Bailie, R. (2006) · Europe PMC (PubMed Central) · Cited by 112
Sullivan, L. E., Chawarski, M., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.12.008 · Cited by 110
Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users
Strain, E. C., Stitzer, M. L., Liebson, I. A., & Bigelow, G. E. (1994) · Psychopharmacology · doi:10.1007/bf02247469 · Cited by 108
Buprenorphine versus methadone maintenance: a cost-effectiveness analysis
Doran, C. M. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00169-8 · Cited by 108
A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence
Kirchmayer, U., Davoli, M., Verster, A. D., Amato, L., Ferri, A., & Perucci, C. A. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00217.x · Cited by 106
Avants, S. K., Margolin, A., Usubiaga, M. H., & Doebrick, C. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(03)00159-4 · Cited by 106
Silverman, K., Robles, E., Mudric, T., Bigelow, G. E., & Stitzer, M. L. (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.5.839 · Cited by 103
Eder, H., Jagsch, R., Kraigher, D., Primorac, A., Ebner, N., & Fischer, G. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.001128.x · Cited by 95
Buprenorphine in the treatment of opioid dependence
Davids, E., & Gastpar, M. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)00146-9 · Cited by 93
Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients
Bickel, W. K., Amass, L., Crean, J. P., & Badger, G. J. (1999) · Psychopharmacology · doi:10.1007/s002130051096 · Cited by 92
Davies, C., English, L., Stewart, C. R., Edginton, M., McVeigh, J., & Bellis, M. A. (2013) · Cited by 91
Alternate-day dosing during buprenorphine treatment of opioid dependence
Amass, L., Bickel, W. K., Higgins, S. T., & Badger, G. J. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00848-5 · Cited by 90
Treating Alcohol and Drug Abuse – An Evidence Based Review
Berglund, P. D. M., Thelander, S., & Jonsson, P. D. E. (2003) · Wiley eBooks · doi:10.1002/3527601465.contrib · Cited by 89
Graham, H. L., Maslin, J., Copello, A. G., Birchwood, M. J., Mueser, K. T., McGovern, D., & Georgiou, G. (2001) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s001270170023 · Cited by 89
A meta-analysis comparing the effectiveness of buprenorphine and methadone
West, S. L., O’Neal, K. K., & Graham, C. W. (2000) · Journal of Substance Abuse · doi:10.1016/s0899-3289(01)00054-2 · Cited by 89
Prognostic Factors in Buprenorphine- versus Methadone-Maintained Patients
Schottenfeld, R. S., Pakes, J., & Kosten, T. R. (1998) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199801000-00006 · Cited by 88
Contingent methadone delivery: Effects on illicit-opiate use
Higgins, S. T., Stitzer, M. L., Bigelow, G. E., & Liebson, I. A. (1986) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(86)90080-3 · Cited by 87
Adolescent heroin use: a review of the descriptive and treatment literature
Hopfer, C. J., Khuri, E. T., Crowley, T. J., & Hooks, S. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00250-7 · Cited by 87
Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing
Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01189-7 · Cited by 86
Eyes Wide Shut? – A Conceptual and Empirical Critique of Methadone Maintenance Treatment
Fischer, B., Rehm, J. T., Kim, G., & Kirst, M. J. (2004) · European Addiction Research · doi:10.1159/000081410 · Cited by 85
Pharmacotherapy for pregnant women with addictions
Rayburn, W. F., & Bogenschutz, M. P. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.06.082 · Cited by 84
Harris, A., Gospodarevskaya, E., & Ritter, A. J. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523010-00007 · Cited by 83
Neri, S., Bruno, C. M., Pulvirenti, D., Malaguarnera, M., Italiano, C., Mauceri, B., Abate, G., Cilio, D., Calvagno, S., Tsami, A., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2239-x · Cited by 83
Darke, S. G., & Ross, J. E. (2000) · Addiction · doi:10.1046/j.1360-0443.2000.9545698.x · Cited by 82
Marsch, L. A., Bickel, W. K., Badger, G. J., & Jacobs, E. A. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.08.011 · Cited by 82
Caplehorn, J. R. M. (1998) · Drug and Alcohol Review · doi:10.1080/09595239800187551 · Cited by 81
Krook, A. L., Brørs, O., Dahlberg, J., Grouff, K., Magnus, P. M., Røysamb, E., & Waal, H. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00090.x · Cited by 81
Pharmacological treatments for heroin and cocaine addiction
van den Brink, W., & van Ree, J. M. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.008 · Cited by 80
Methadone Maintenance and HIV Prevention: A Cost-Effectiveness Analysis
Zaric, G. S., Brandeau, M. L., & Barnett, P. G. (2000) · Management Science · doi:10.1287/mnsc.46.8.1013.12025 · Cited by 79
Drug misuse declared: Findings from the 2005/06 British Crime Survey
Roe, S., & Man, L. (2006) · PsycEXTRA Dataset · doi:10.1037/e422542008-001 · Cited by 79
Dean, A. J., Bell, J., Christie, M. J., & Mattick, R. P. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.09.002 · Cited by 78
Benefits and costs of methadone treatment: results from a lifetime simulation model
Zarkin, G. A., Dunlap, L. J., Hicks, K. A., & Mamo, D. (2005) · Health Economics · doi:10.1002/hec.999 · Cited by 76
Batki, S. L., Gruber, V. A., Bradley, J. M., Bradley, M., & Delucchi, K. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00208-3 · Cited by 75
Mitchell, T. B., White, J. M., Somogyi, A. A., et al. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00764.x · Cited by 75
A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial.
Caplehorn, J. R. M. (2003) · PubMed · doi:10.5694/j.1326-5377.2003.tb05417.x · Cited by 74
The medical status of methadone maintenance patients in treatment for 11–18 years
Novick, D. M., Richman, B. L., Friedman, J. M., Friedman, J. E., Fried, C., Wilson, J. P., Townley, A., & Kreek, M. J. (1993) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(93)90110-c · Cited by 72
van Ameijden, E. J. C., Langendam, M. W., & Coutinho, R. A. (1999) · Addictive Behaviors · doi:10.1016/s0306-4603(98)00083-5 · Cited by 71
Amass, L. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00141-1 · Cited by 71
Simoens, S., Matheson, C., Bond, C. M., Inkster, K., & Ludbrook, A. (2005) · PubMed · Cited by 70
Carpenter, K. M., Brooks, A. C., Vosburg, S. K., & Nunes, E. V. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.11.015 · Cited by 69
Optimizing Long-Term Response to Methadone Maintenance Treatment
Maxwell, S., & Shinderman, M. S. (2002) · Journal of Addictive Diseases · doi:10.1300/j069v21n03_01 · Cited by 69
Behavioral contingencies improve counseling attendance in an adaptive treatment model
Brooner, R. K., KIDORF, M. S., King, V. L., Stoller, K. B., Peirce, J. M., Bigelow, G. E., & Kolodner, K. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2004.07.005 · Cited by 68
Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans
Amass, L., Bickel, W. K., Crean, J. P., Blake, J. E., & Higgins, S. T. (1998) · Psychopharmacology · doi:10.1007/s002130050559 · Cited by 67
PRENDERGAST, M. L., Podus, D., & Chang, E. Y. (2000) · Substance Use & Misuse · doi:10.3109/10826080009148246 · Cited by 66
A multicenter randomized evaluation of methadone medical maintenance.
King, V., Stoller, K. B., Hayes, M., Umbricht, A., Currens, M., Kidorf, M., Carter, J., Schwartz, R., & Brooner, R. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00155-7 · Cited by 65
Masson, C. L., Barnett, P. G., Sees, K. L., Delucchi, K., Rosen, A. B., Wong, W., & Hall, S. M. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00728.x · Cited by 63
Thrice-weekly versus daily buprenorphine maintenance
Schottenfeld, R. S., Pakes, J., O’Connor, P. G., Chawarski, M. C., Oliveto, A. H., & Kosten, T. R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00270-x · Cited by 60
Costs and Effects of Chlamydial Screening: Dynamic versus Static Modeling
Welte, R., Postma, M. J., Leidl, R., & Kretzschmar, M. (2005) · Sexually Transmitted Diseases · doi:10.1097/01.olq.0000161181.48687.cf · Cited by 59
Ahmadi, J., Ahmadi, K., & Ohaeri, J. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2003.01218.x · Cited by 58
Treatment Effectiveness Score as an Outcome Measure in Clinical Trials
Ling, W. W., SHOPTAW, S. J., Wesson, D., Rawson, R. A., Compton, M., & Klett, C. J. (1997) · PsycEXTRA Dataset · doi:10.1037/e495552006-011 · Cited by 58
Zanis, D. A., Coviello, D. M., Alterman, A., & Appling, S. E. (2001) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(01)00177-5 · Cited by 56
Network therapy: Decreased secondary opioid use during buprenorphine maintenance
Galanter, M. S., Dermatis, H., Glickman, L., Maslansky, R. A., Sellers, M. B., Neumann, E., & Rahman-Dujarric, C. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2004.03.002 · Cited by 56
Mitchell, T. B., White, J. M., Somogyi, A. A., & Bochner, F. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00190-x · Cited by 56
Lintzeris, N., Ritter, A. J., Panjari, M., Clark, N. C., Kutin, J. J., & Bammer, G. (2004) · American Journal on Addictions · doi:10.1080/10550490490440799 · Cited by 56
Self-citationThe Effectiveness of Drug Abuse Treatment: Implications for Controlling AIDS/HIV Infection
Sisk, J. E., Hatziandreu, E. J., & Hughes, R. A. (1990) · DigitalGeorgetown (Georgetown University Library) · Cited by 56
Abstinence reinforcement maintenance contingency and one-year follow-up.
Preston, K., Umbricht, A., & Epstein, D. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00023-6 · Cited by 52
KIDORF, M. S., Stitzer, M. L., Brooner, R. K., & Goldberg, J. S. (1994) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(94)90148-1 · Cited by 52
Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients
Ahmadi, J. (2003) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(03)00024-2 · Cited by 52
Gonzalez, G. M., Feingold, A., Oliveto, A. H., Gonsai, K., & Kosten, T. R. (2003) · The American Journal of Drug and Alcohol Abuse · doi:10.1081/ada-120023455 · Cited by 51
A novel cognitive-behavioral approach for treatment-resistant drug dependence
Pollack, M. H., Penava, S. J., Bolton, E. E., Worthington, J. J., Lanka, G. D., Farach, F. J., & Otto, M. W. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00298-2 · Cited by 50
Jones, H. E., Johnson, R. E., Jasinski, D. R., & Milio, L. A. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.08.027 · Cited by 49
Is methadone too dangerous for opiate addiction?
Luty, J. S., OʼGara, C., & Sessay, M. (2005) · BMJ · doi:10.1136/bmj.331.7529.1352 · Cited by 44
Blanken, P., Hendriks, V. M., Koeter, M. W. J., van Ree, J. M., & van den Brink, W. (2004) · Addiction · doi:10.1111/j.1360-0443.2005.00937.x · Cited by 42
Methadone withdrawal psychosis.
Levinson, I., GALYNKER, I. I., & Rosenthal, R. N. (1995) · PubMed · Cited by 42
Petry, N. M., Bickel, W. K., & Badger, G. J. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.9668234.x · Cited by 41
Newcombe, R. G. (1999) · Postgraduate Medical Journal · doi:10.1136/pgmj.75.885.447d · Cited by 38
Effects of urine testing frequency on outcome in a methadone take-home contingency program
Chutuape, M. A., Silverman, K., & Stitzer, M. L. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00160-5 · Cited by 37
Layson-Wolf, C., Goode, J. R., & Small, R. E. (2002) · PubMed · Cited by 37
Efficacy of Buspirone in the Treatment of Opioid Withdrawal
Buydens‐Branchey, L., Branchey, M. H., & Reel-Brander, C. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162804.38829.97 · Cited by 35
Glanz, M., Klawansky, S., McAullife, W., & Chalmers, T. C. (1997) · PubMed · Cited by 33
Dean, A. J., Bell, J., Mascord, D. J., Parker, G. B., & Christie, M. J. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00419-0 · Cited by 31
Lidz, V., Sorrentino, D. M., Robison, L., & Bunce, S. C. (2004) · Substance Use & Misuse · doi:10.1081/ja-200034631 · Cited by 30
Assessing the relationship between maternal opiate use and antepartum haemorrhage
Hulse, G. K., Milne, E., English, D. R., & Holman, C. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9310155312.x · Cited by 30
Methadone withdrawal psychosis
Levinson, I., GALYNKER, I. I., & Rosenthal, R. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90935-0 · Cited by 29
Newcombe, D. A. L., Bochner, F., White, J. M., & Somogyi, A. A. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.04.004 · Cited by 28
Poirier, M. F., Laqueille, X., Jalfre, V., Willard, D., Bourdel, M., Fermanian, J., & Olié, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.10.003 · Cited by 28
Relationship between LAAM–methadone preference and treatment outcomes
White, J. M., Danz, C., Kneebone, J., Vincente, S. F. L., Newcombe, D. A. L., & Ali, R. L. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00007-8 · Cited by 27
Treating Alcohol and Drug Abuse. An Evidence Based Review.
Rist, F. (2004) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/2004.03.09 · Cited by 26
Outpatient Methadone Withdrawal for Heroin Dependence
Maddux, J. F., Desmond, D. P., & Esquivel, M. (1980) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998008993430 · Cited by 26
Buprenorphine maintenance treatment of heroin dependence: the first experience from Iran
Ahmadi, J. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00222-2 · Cited by 26
Lofwall, M. R., Stitzer, M. L., Bigelow, G. E., & Strain, E. C. (2005) · Addictive Disorders & Their Treatment · doi:10.1097/01.adt.0000145126.17405.6a · Cited by 22
Groß, A., Jacobs, E. A., Petry, N. M., Badger, G. J., & Bickel, W. K. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00227-1 · Cited by 21
Buprenorphine induction and stabilisation in the treatment of opiate dependence
Doran, C. M., Holmes, J., Ladewig, D., & Ling, W. W. (2005) · Heroin addiction and related clinical problems · Cited by 20
Margolin, A., Copenhaver, M., Avants, S. K., & Kantak, K. M. (2003) · Journal of Addictive Diseases · doi:10.1300/j069v22n02_04 · Cited by 19
Buprenorphine treatment of opium-dependent outpatients seeking treatment in Iran
Ahmadi, J., & Bahrami, N. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00272-6 · Cited by 19
A cost-effectiveness model for evaluating health care programs: application to drug abuse treatment.
Pg, G. (1976) · PubMed · Cited by 19
&NA; (2001) · Survey of Anesthesiology · doi:10.1097/00132586-200104000-00058 · Cited by 19
[Buprenorphine and methadone to opiate addicts--a randomized trial].
Kristensen, Ø., Espegren, O., Åsland, R., et al. (2005) · PubMed · Cited by 18
Treatment of Comorbid Affective and Substance Use Disorders Therapeutic Potential of Anticonvulsants
Donovan, S. J., & Nunes, E. V. (1998) · American Journal on Addictions · doi:10.3109/10550499808998353 · Cited by 18
Effectiveness of Vocational Problem-Solving Skills on Motivation and Job-Seeking Action Steps
Coviello, D. M., Zanis, D. A., & Lynch, K. G. (2004) · Substance Use & Misuse · doi:10.1081/ja-200034625 · Cited by 18
Sigmon, S. C., Correia, C. J., & Stitzer, M. L. (2004) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.12.4.269 · Cited by 16
A cost ‐ effectiveness analysis of buprenorphine‐assisted heroin withdrawal
Doran, C. M., Shanahan, M., Bell, J. R., & Gibson, A. (2004) · Drug and Alcohol Review · doi:10.1080/095952304100017044154 · Cited by 15
Kreek, M. J. (1997) · Seminars in Neuroscience · doi:10.1006/smns.1997.0114 · Cited by 15
Controlled trial of maintenance treatment of intravenous buprenorphine dependence
Ahmadi, J., & Ahmadi, K. (2003) · Irish Journal of Medical Science (1971 -) · doi:10.1007/bf02915283 · Cited by 15
Interpersonal maladjustment as predictor of mothers’ response to a relational parenting intervention
Suchman, N. E., McMahon, T. J., & Luthar, S. S. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2004.06.003 · Cited by 15
A critical appraisal of the Australian comparative trial of methadone and buprenorphine maintenance
Caplehorn, J. R. M., & Deeks, J. J. (2006) · Drug and Alcohol Review · doi:10.1080/09595230600681527 · Cited by 11
Psychosocial Treatment for Drug Dependence
Fridell, M. (2003) · Wiley eBooks · doi:10.1002/3527601465.ch6 · Cited by 10
Twelve-month maintenance treatment of heroin-dependent outpatients with buprenorphine
Ahmadi, J., & Ahmadi, J. (2003) · Journal of Substance Use · doi:10.1080/14659890306270 · Cited by 9
Improving the Quality of Substance Dependency Treatment with Pharmacotherapy
Boyarsky, B. K., & McCance‐Katz, E. F. (2000) · Substance Use & Misuse · doi:10.3109/10826080009148251 · Cited by 7
Lofexidine for opiate detoxification
Bearn, J. (2004) · Acta Neuropsychiatrica · doi:10.1111/j.0924-2708.2004.00094.x · Cited by 4
Cited by
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6501e1 · Cited by 2,697
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies
Volkow, N. D., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1507771 · Cited by 1,305
Metadata
- Authors
- Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., Burls, A., & Taylor, R.
- Venue
- Health Technology Assessment
- Published
- 2007-03
- Volume
- 11
- Issue
- 9
- Pages
- 1-171, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2081812523
- Cited by
- 585
- References
- 174
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.